Charleston Laboratories, Inc. Announces Research Collaboration with Stanford University

JUPITER, Fla., Oct. 9, 2013 /PRNewswire/ -- Charleston Laboratories, Inc, an emerging specialty pharmaceutical company focused on the research and development of novel pain products that prevent or significantly reduce nausea and vomiting related to opioid analgesics and other pain associated disease states, announced today the commencement of a research program to evaluate anti-emetic effects on opioid-induced hyperalgesia and physical dependence with the Anesthesiology, Pain and Perioperative Medicine department at Stanford's School of Medicine. 

"The Charleston team is delighted to be a part of this research with Dr. David Yeomans and his lab" said Mr. Paul Bosse, President and Chief Executive Officer of Charleston. "This program leverages complementary interest and could possibly yield some applicable innovation to further differentiate Charleston's pipeline of products."

About Charleston Laboratories, Inc.

Charleston Laboratories, Inc is a specialty pharmaceutical company focused on the research and development of novel pain products that prevent or significantly reduce nausea and vomiting, the two most burdensome side effects related to opioid analgesics and other pain associated disease states. Charleston's new products will address Opioid Induced Nausea and Vomiting (OINV), Postoperative Nausea and Vomiting (PONV), Chemotherapy Induced Nausea and Vomiting (CINV), Radiation Induced Nausea and Vomiting (RINV), and Migraine Induced Nausea and Vomiting (MINV).  In addition, Charleston is developing other products without acetaminophen to reduce the potential for liver injury and formulations with abuse deterrent technologies designed to curb misuse and abuse. Charleston Laboratories intends to enter into discovery and commercialization alliances with partners motivated to introduce novel pain therapies that eliminate or significantly reduce nausea and vomiting.

www.charlestonlabs.com.

SOURCE Charleston Laboratories, Inc.